You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Highly potent active component of activity-dependent neuroprotective protein (ADNP). Prevents β-amyloid aggregation. Reduces hyperphosphorylated tau levels and increases tau-microtubule interactions; neuroprotective at femtomolar concentrations in vitro. Exerts neuroprotective effects in schizophrenia models associated with microtubule-autophagy insufficiency in MAP6-deficient mice. Modulates HIFs and VEGF expression and suppresses retinal cell apoptosis in an in vivo diabetic retinopathy model.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 1 mg/ml in water|
References are publications that support the biological activity of the product.
Bassan et al (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J.Neurochem. 72 1283 PMID: 10037502
Gozes et al (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze J.Pharmacol.Exp.Ther. 293 1091 PMID: 10869414
Sragovich et al (2017) ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease. Bioessays 39 doi: 10.1002 PMID: 28940660
Melo et al (2017) Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. Exp.Brain Res. 235 731 PMID: 27866262
D'Amico et al (2018) NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. J.Cell Physiol. 233 1120 PMID: 28436035
Ivashko-Pachima et al (2017) ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry 22 1335 PMID: 28115743
If you know of a relevant reference for Davunetide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Davunetide, Davunetide supplier, AL-108, NAP, (peptide), NAPVSIPQ, Amyloid, Beta, Peptides, Microtubules, 6779, Tocris Bioscience
Citations for Davunetide
Citations are publications that use Tocris products.
Currently there are no citations for Davunetide. Do you know of a great paper that uses Davunetide from Tocris? Please let us know.
Reviews for Davunetide
There are currently no reviews for this product. Be the first to review Davunetide and earn rewards!
Have you used Davunetide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.